Furthermore, FCGR2A is reportedly associated with the pharmacodynamics of monoclonal antibodies in different cancer types, such as colorectal cancer [39], breast cancer [40], and metastatic squamous cell head and neck cancer [41]. The gene discussed is FCGR2A; the disease is breast cancer.